Suppr超能文献

继发性红细胞增多症患者静脉血栓栓塞症的患病率。

Prevalence of venous thromboembolism in patients with secondary polycythemia.

机构信息

Department of Medicine, Dartmouth-Hitchcock Medical Center Lebanon, NH, USA.

出版信息

Clin Appl Thromb Hemost. 2013 Jul-Aug;19(4):363-6. doi: 10.1177/1076029612460425. Epub 2012 Sep 23.

Abstract

To investigate an association between secondary polycythemia and venous thromboembolism (VTE) risk, we performed a case-control study to compare the prevalence of VTE in participants with secondary polycythemia due to chronic obstructive pulmonary disease (COPD; N = 86) to that in age- and sex-matched controls with COPD without secondary polycythemia (N = 86). Although there was a significant difference in mean hematocrit between cases and controls (53.5% vs 43.6%, respectively; P < .005), we identified no difference in the number of total or idiopathic VTE events in the 2 groups. Patients with VTE, however, had a significantly higher body mass index than patients without VTE. Our findings suggest that secondary polycythemia alone may not be a significant risk factor for VTE but that VTE risk in this population may be related to known risk factors such as obesity. The role of phlebotomy for VTE risk reduction secondary polycythemia is therefore questionable.

摘要

为了研究继发性红细胞增多症与静脉血栓栓塞症(VTE)风险之间的关联,我们进行了一项病例对照研究,比较了因慢性阻塞性肺疾病(COPD)导致的继发性红细胞增多症患者(N=86)与年龄和性别匹配的无继发性红细胞增多症 COPD 患者(N=86)中 VTE 的患病率。尽管病例组和对照组的平均血细胞比容存在显著差异(分别为 53.5%和 43.6%;P<.005),但我们未发现两组总 VTE 或特发性 VTE 事件的数量存在差异。然而,患有 VTE 的患者的体重指数明显高于未患有 VTE 的患者。我们的研究结果表明,单纯的继发性红细胞增多症可能不是 VTE 的重要危险因素,但该人群的 VTE 风险可能与肥胖等已知危险因素有关。因此,放血疗法降低继发性红细胞增多症相关 VTE 风险的作用尚存在争议。

相似文献

1
Prevalence of venous thromboembolism in patients with secondary polycythemia.
Clin Appl Thromb Hemost. 2013 Jul-Aug;19(4):363-6. doi: 10.1177/1076029612460425. Epub 2012 Sep 23.
3
COPD disease severity and the risk of venous thromboembolic events: a matched case-control study.
Int J Chron Obstruct Pulmon Dis. 2016 Apr 28;11:899-908. doi: 10.2147/COPD.S100533. eCollection 2016.
5
COPD and risk of venous thromboembolism and mortality in a general population.
Eur Respir J. 2016 Feb;47(2):473-81. doi: 10.1183/13993003.00402-2015. Epub 2015 Nov 19.
6
Serum levels of 25(OH)D are not associated with venous thromboembolism in the elderly population. A case-control study.
Thromb Haemost. 2016 Jan;115(1):169-75. doi: 10.1160/TH15-02-0148. Epub 2015 Nov 5.
7
Association between features of COPD and risk of venous thromboembolism.
Clin Respir J. 2019 Aug;13(8):499-504. doi: 10.1111/crj.13051. Epub 2019 Jun 7.
10
Venous thromboembolism in nursing home residents: role of selected risk factors.
J Am Geriatr Soc. 2012 Sep;60(9):1718-23. doi: 10.1111/j.1532-5415.2012.04100.x. Epub 2012 Aug 6.

引用本文的文献

3
Gender-affirming hormone therapy in the transgender patient: influence on thrombotic risk.
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):652-663. doi: 10.1182/hematology.2024000592.
4
Erythrocytosis in Gender-Affirming Care With Testosterone.
Ann Fam Med. 2023 Sep-Oct;21(5):403-407. doi: 10.1370/afm.3018.
5
Inferior mesenteric vein thrombosis in the setting of testosterone therapy.
BMJ Case Rep. 2022 Dec 14;15(12):e251886. doi: 10.1136/bcr-2022-251886.
6
Polycythemia-Related Proliferative Ischemic Retinopathy Managed with Smoking Cessation: A Case Report.
Int J Environ Res Public Health. 2022 Jun 30;19(13):8072. doi: 10.3390/ijerph19138072.
7
Obstructive Sleep Apnea is Associated with an Increased Prevalence of Polycythemia in Patients with Chronic Obstructive Pulmonary Disease.
Int J Chron Obstruct Pulmon Dis. 2022 Jan 15;17:195-204. doi: 10.2147/COPD.S338824. eCollection 2022.
9
Secondary polycythemia in chronic obstructive pulmonary disease: prevalence and risk factors.
BMC Pulm Med. 2021 Jul 14;21(1):235. doi: 10.1186/s12890-021-01585-5.
10
JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views.
Leukemia. 2021 Aug;35(8):2166-2181. doi: 10.1038/s41375-021-01290-6. Epub 2021 May 21.

本文引用的文献

3
JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.
Exp Hematol. 2009 Sep;37(9):1016-21. doi: 10.1016/j.exphem.2009.06.006. Epub 2009 Jun 24.
4
Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
Blood. 2009 Jul 23;114(4):759-63. doi: 10.1182/blood-2009-02-206797. Epub 2009 Apr 16.
5
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
Leukemia. 2008 Nov;22(11):2020-8. doi: 10.1038/leu.2008.253. Epub 2008 Sep 18.
6
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Blood. 2008 Nov 15;112(10):4061-8. doi: 10.1182/blood-2008-06-164087. Epub 2008 Sep 3.
7
Hypercoagulability and tissue factor gene upregulation in hematologic malignancies.
Semin Thromb Hemost. 2008 Mar;34(2):204-10. doi: 10.1055/s-2008-1079262.
8
Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Haematologica. 2008 Mar;93(3):331-5. doi: 10.3324/haematol.12604.
9
The haematocrit and platelet target in polycythemia vera.
Br J Haematol. 2007 Jan;136(2):249-59. doi: 10.1111/j.1365-2141.2006.06430.x. Epub 2006 Dec 8.
10
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.
Blood. 2007 Mar 15;109(6):2446-52. doi: 10.1182/blood-2006-08-042515. Epub 2006 Nov 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验